Anti-vascular Endothelial Growth Factor Therapeutics Market By Drug Type (Bevacizumab, Ranibizumab, Aflibercept, Brolucizumab), By Application (Ophthalmology {Age-related Macular Degeneration, Diabetic Retinopathy, Retinal Vein Occlusion}, Oncology {Colorectal Cancer, Non-Small Cell Lung Cancer, Breast Cancer}, Other Indications), By Delivery Route (Intravitreal Injection, Intravenous Injection), By End-User (Hospitals, Specialty Clinics, Ambulatory Centers), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

Industry Outlook

The Anti-vascular Endothelial Growth Factor Therapeutics Market accounted for USD 13.56 Billion in 2024 and is expected to reach USD 15.55 Billion by 2035, growing at a CAGR of around 1.25% between 2025 and 2035. The Anti-vascular Endothelial Growth Factor Therapeutics Market is focused on treatments that inhibit VEGF, a protein factor that promotes the growth of blood vessels, especially in the case of tumors. They are mainly used in the field of oncology to target and block abnormal blood vessel growth in cancers such as colorectal, lung, and breast cancer, and in diseases of the retina, such as age-related macular degeneration and diabetic retinopathy.

Anti-VEGF drugs work by suppressing the angiogenesis of the tumor, starving it of oxygen and nutrients necessary for its growth. Growth in the market occurs with the increasing incidence of both cancer and retinal diseases due to the development of more focused and effective treatments. Pharmaceutical companies in this market include Roche and Regeneron, companies that focus on innovation through the expansion of indications.

Report Scope:

Market Dynamics

Rising Prevalence of Cancer and Retinal Diseases Driving Market Demand for Treatments

The Anti-vascular Endothelial Growth Factor Therapeutics Market is a rapidly growing market due to the growing incidence of cancer and retinal disorders. One of the most prevalent illnesses that claim many lives is cancer, and the number of new cases is only expected to rise. Because tumors require angiogenesis or the formation of new blood vessels on which to extend themselves and spread, anti-VEGF therapies work to counter this process and significantly slow tumor growth.

On the same note, retinal diseases like AMD and DR, which are on the rise due to the prevalence of the aging population and type II diabetes, benefit from treatments that use anti-VEGF. Anti-VEGF medications have been demonstrated to significantly improve arrests of the advancement of these disorders, which are characterized by the growth of new blood vessels in the retina that may result in vision loss. As these illnesses become more common, there will probably be a greater demand for targeted, precise treatments like anti-VEGF, which will continue to be important for the industry.

Increasing Adoption of Targeted Therapies and Personalized Medicine in Oncology Worldwide

The Anti-vascular Endothelial Growth Factor Therapeutics Market continues to have strong growth due to the growing role of targeted therapies and individualized approaches in cancer treatment. Strategic therapies that include anti-VEGF therapies seek to arrest the processes that cause cancer growth by addressing VEGF, a protein that plays a central role in creating new blood vessels in a tumor. This change towards more accurate cancer treatments that target malignant cells more effectively has gradually been picking up ground across the globe, especially since the increase in the uptake of personalized medicine practice.

Targeted therapy, also known as molecular therapy, is a customized treatment strategy that maximizes advantages by accounting for a person's genes, molecules, and surroundings. This means that physicians can provide patients with better and more efficient treatment programs by combining anti-VEGF medications with other targeted medicines. The market for anti-VEGF therapies is steadily rising as a result of these cutting-edge technological developments in precision oncology that guarantee the administration of chemicals or radiation therapy just to cancer cells while avoiding healthy tissues.

High Treatment Costs Limiting Accessibility for Patients in Low-Income and Rural Regions

The high expense of anti-VEGF agent treatment is a significant barrier to the market, limiting access for low-income and rural populations. Although very effective, anti-VEGF medications such as Bevacizumab and Aflibercept are expensive due to their extensive research, development, and manufacturing. Consequently, the high costs deter those who need ongoing care for diseases like cancer and retinal abnormalities from seeking therapy. In low-income communities, where many patients are unfortunately unable to receive the therapies, they need to survive, the availability of medical care in the form of these medications becomes vital. Additionally, the high cost makes it difficult for medical facilities in underdeveloped nations to access those therapies, which results in an uneven distribution. Therefore, the public's access to anti-VEGF medicines is restricted by their high cost, which counteracts the market's overall growth in high-risk countries with constrained healthcare budgets.

Growing Opportunities in Developing Countries for Cancer and Retinal Disease Treatments

The Anti-vascular Endothelial Growth Factor Therapeutics Market is constantly expanding in developing countries due to the continuously increasing incidence of cancer and retinal diseases. With the development of the healthcare system in EM, there is an increasing need for more sophisticated products such as anti-VEGF therapies.

Governments are planning to make health care services more inexpensive, and more and more individuals are receiving treatment as a result of the availability of better services. New anti-VEGF treatment efforts ought to be started. Consequently, the expansion of accessibility and reduction in expenses of these treatments due to domestic manufacturing and advantageous price reductions offer substantial opportunities for capturing these unexplored markets.

Rising Research and Development Investments for New Anti-VEGF Drug Formulations Worldwide

Research on the creation of novel medication formulations offers the Anti-vascular Endothelial Growth Factor Therapeutics Market a substantial opportunity. Pharmaceutical firms are specifically trying to develop more effective, safer, and longer-acting anti-VEGF medications that are more precisely targeted. Two well-liked tactics being investigated to increase the possibility of compelling patients to take their drugs as directed are the usage of combination therapy and the newly developed sustained-release formulation of the drug.

Additional research into new targets and anti-VEGF reagents is opening up new therapeutic applications for anti-VEGF medications, focusing more on vascular problems than cancer and eye conditions. Creating new opportunities will increase the applications of anti-VEGF medicines, which will increase their use worldwide. The market will continue to grow as a result of these trends toward higher R&D expenditures, giving pharmaceutical companies more chances to control the market.

Industry Experts Opinion

“This class of drugs represents a huge leap in treatment for macular degeneration. Doctors have been blown away by the results. Ten years ago, wet AMD was a one-way ticket to blindness, but now I have patients with the condition who can read and drive; and some even maintain 20/20 vision."

• Rahul Khurana, Clinical Spokesperson, American Academy of Ophthalmology and Retina.

Segment Analysis

Based on Drug type, the Anti-vascular Endothelial Growth Factor Therapeutics Market is divided into Bevacizumab, Ranibizumab, Aflibercept, and Brolucizumab. Aflibercept is a very important and representative drug in the Anti-vascular Endothelial Growth Factor Therapeutics Market. This wide applicability in the treatment of disorders such as age-related macular degeneration, diabetic macular edema, and retinal vein occlusion makes it the preferred option for doctors. This is because the use of the drug involves longer intervals and requires less burden on patients, thus improving compliance. Its favourable clinical performance and high usage rate additionally strengthen its position in this segment of the market.

Based on Application, the Anti-vascular Endothelial Growth Factor Therapeutics Market is broadly segmented into oncology and ophthalmology. Ophthalmology, which mainly relates to the treatment of AMD through the Anti-vascular Endothelial Growth Factor Therapeutics Market, is the largest segment in the Anti-vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics Market. AMD is a major cause of blindness throughout the world, and therefore, there is going to be a substantial need for effective treatments such as anti-VEGF agents. These treatments uphold vision because they prevent the growth of new vessels and seepage of fluid in the retinal area. The first reason is the rise in the incidence of AMD, a disease that is successfully treated with the usage of anti-VEGF drugs; the second reason remains with ophthalmology.

Regional Analysis

The North American Anti-Vascular Endothelial Growth Factor Therapeutics Market is leading due to the high incidence of cancer and other retinal diseases, along with having well-developed healthcare facilities. With its widespread use of anti-VEGF treatments for a variety of cancers, such as colorectal, breast, and non-small cell lung cancer, AMD, and diabetic retinopathy, the United States is the most developed country in this region. The area has a robust healthcare system, spends a lot of money on healthcare, and hasn't slackened off in creating new treatment methods. The presence of many key industry players, large pharma players, including Roche and Regeneron, establishes North America’s dominance in the market.

Asia-Pacific the Anti-vascular Endothelial Growth Factor Therapeutics Market is expanding rapidly due to several factors, including growing investment in the healthcare sector, increasing incidence of cancer and retinal diseases, and improving availability of modern medical services. Large, populated countries like China and India have huge untapped market prospects due to increasing population bases, health consciousness, and increasing incidence of diseases such as cancer, diabetic retinopathy, etc. This has resulted in the increased need for new solutions, including anti-VEGF therapies.

Competitive Landscape

The Anti-vascular Endothelial Growth Factor Therapeutics Market’s competition profile is quite saturated due to the major pharma companies. The market is dominated by major players, including Roche, Regeneron Pharmaceuticals, Bayer, etc., having approved product profiles like Bevacizumab (Avastin) and Aflibercept (Eylea) used for cancer and retinal ailments, respectively. Businesses are aspiring to innovate, formulate better drugs, and widen the use of their products in the market, all to improve their market share.

Because of the increasing number of biotech companies in the industry as well as the commitments made through acquisitions and strategic partnerships, competition is becoming fiercer. In addition to encouraging competition, it teaches how to create more cost-effective biosimilars. One of the key factors propelling this sector is the constant investment in R&D to discover better treatment approaches.

Anti-vascular Endothelial Growth Factor Therapeutics Market, Company Shares Analysis, 2024

To explore in-depth analysis in this report - Request Free Sample Report

Recent Developments:

• In February 2024, Bausch Health Companies Inc.'s majority-owned subsidiary Bausch + Lomb Corporation announced the receipt of the Category 1 CPT code 67516 from the American Medical Association, in collaboration with the American Society of Retina Specialists and American Academy of Ophthalmology (AAO), for XIPERE. This injectable suspension of triamcinolone acetonide is indicated for macular edema due to uveitis.

Report Coverage:

By Drug Type

• Bevacizumab
• Ranibizumab
• Aflibercept
• Brolucizumab
• Other

 By Application

• Ophthalmology
  • Age-related Macular Degeneration
  • Diabetic Retinopathy
  • Retinal Vein Occlusion
• Oncology
  • Colorectal Cancer
  • Non-Small Cell Lung Cancer
  • Breast Cancer
• Other Indications

By Delivery Route

• Intravitreal Injection
• Intravenous Injection

By End-User

• Hospitals
• Specialty Clinics
• Ambulatory Surgical Centers

By Region

North America

• U.S.
• Canada

Europe

• U.K.
• France
• Germany
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC Countries
• South Africa
• Rest of the Middle East & Africa

List of Companies:

• Roche
• Regeneron Pharmaceuticals
• Novartis
• Bayer AG
• Eli Lilly and Company
• Amgen Inc.
• Pfizer Inc.
• Sanofi
• AstraZeneca
• Merck & Co., Inc.
• Teva Pharmaceutical Industries
• Bristol-Myers Squibb
• GlaxoSmithKline
• Bausch & Lomb
• Alcon Laboratories
• Santen Pharmaceutical Co., Ltd.
• Haplo Therapeutics
• Zymeworks Inc.

Frequently Asked Questions (FAQs)